Navigation Links
Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
Date:6/6/2009

n Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.orexigen.com.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the efficacy and safety of Contrave, the enrollment, timing, execution and completion of clinical trials of the Company's product candidates, the potential for, and timing of, an NDA submission for Contrave, and the potential to obtain regulatory approval for, and effectively treat obesity with, Contrave and Empatic. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: the final analyses of data from the NB-302 trial and other clinical trials of Contrave may produce negative or inconclusive results, or may be inconsistent with previously conducted clinical trials, and
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Orexigen(R) Therapeutics Announces Upcoming Data Presentations at American Diabetes Association and Endocrine Society Annual Scientific Meetings
2. Orexigen(R) Therapeutics to Present at Upcoming Meetings
3. Orexigen(R) Therapeutics Announces Jay Hagan as Senior Vice President, Corporate Development and Strategy
4. Orexigen(R) Therapeutics to Speak at Upcoming Conferences
5. Orexigen(R) Therapeutics Announces First Quarter 2009 Financial Results
6. Orexigen(R) Therapeutics Names Michael Scaife Senior Vice President of Regulatory Affairs and Product Development, Contrave(R) Program
7. Orexigen(R) Therapeutics Schedules March 12, 2009 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2008
8. Orexigen(R) Therapeutics to Speak at BIO CEO & Investor Conference
9. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
10. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
11. Orexigen(R) Therapeutics Announces Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... Vermillion, Inc. (Pink Sheets: VRML), ... C. Wallen, Ph.D. Chief Scientific Officer, Senior ... Laboratories, will be joining its board of ... ,, "Bill brings more than 20 ... and biotechnology," said Gail Page, Vermillion Executive ...
(Date:12/14/2009)... Corporation (NYSE: BSX ) today announced the ... principal amount of its senior notes under the Company,s ... $850 million of 4.50 percent notes due January 2015, ... and $300 million of 7.375 percent notes due January ... proceeds for general corporate purposes, including prepaying its bank ...
(Date:12/14/2009)... completed the delivery of Brookfield Engineering’s Powder Flow Tester – ... with a smaller footprint and more compact design. , ... ... -- ThermoFab, a US-based thermoforming company, has completed the delivery ... from sheet metal to a plastic enclosure with a smaller ...
(Date:12/11/2009)... miRagen Therapeutics, Inc., a biopharmaceutical company focused on ... for cardiovascular and muscle disease, today announced the ... a crucial role in the progression of amyotrophic ... in neuromuscular synaptic regeneration in mice. The ... the journal Science , reveal miR-206 as ...
Breaking Biology Technology:Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 2Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 3Vermillion Announces Appointment of William C. Wallen, Ph.D. to Board of Directors 4Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 2Boston Scientific Announces Completion of $2 Billion Senior Notes Offering 3Thermofab Helps Brookfield Engineering Move To A Compact Custom Plastic Enclosure 2miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2
... Mass., Feb. 17 Idenix Pharmaceuticals, Inc. (Nasdaq: ... development of drugs for the treatment of human viral and ... fourth quarter and year ended December 31, 2008. At December ... $46.1 million. Business Highlights , , ...
... TechniKrom, Inc. and Asahi Kasei,Medical Co., Ltd., who ... for use with Planova(TM) virus removal filters,have reached ... Asahi Kasei Medical,s full ownership. The integration of,operations ... Kasei TechniKrom, Inc., a,wholly owned subsidiary of Asahi ...
... Inc., a biotechnology company delivering breakthrough therapies in ... is a SILVER level sponsor of the 2009 ... conference, put on by the Alzheimer,s Association, is ... 2009 will take place July 11-16 in Vienna, ...
Other Biology Technology:Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 2Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 3Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 4Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 5Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 6Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results 7TechniKrom's Biopharmaceutical Equipment Operations to be Integrated With Asahi Kasei Medical 2Accera, Inc. Sponsors Alzheimer's Association's 2009 ICAD Conference 2
(Date:12/15/2009)... available in German ., Despite the ... the globe, cultures vary as to how space is ... use egocentric terms such as ,left, right, front, back, ... like ,north, south, east, west, at all times for ... or "There is an snake by your Northern leg". ...
(Date:12/15/2009)... near future, consumers can look forward to ultra-low ... laptops, PDAs and mobile phones. This is made ... technologies which are critical elements for power optimisation ... systems. , Analog IC design is the key ... To pre-position the nation in advanced analog and ...
(Date:12/15/2009)... Va., Dec. 15 The PTR Group, a ... announced that it has agreed to sponsor three high ... FIRST Robotics Competition ( http://usfirst.org ). ,, ... school teams in three different states. The teams ... Rockwall, TX, and James Madison HS in Vienna, VA ...
Breaking Biology News(10 mins):More than a jump to the left 2NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 2NTU and EDB launch S$50 million ($36 million) integrated circuit design research center 3The PTR Group Announces Financial and Technical Support to US FIRST Robotics Competition Teams 2Study Details Swine Flu Transmission Rates 55637 1Study Details Swine Flu Transmission Rates 55637 2Study Details Swine Flu Transmission Rates 55637 3America Needs More Physician Hospitals 55635 1America Needs More Physician Hospitals 55635 2New tool to predict the risk of death in COPD may help physicians to individualize treatment 55633 1New tool to predict the risk of death in COPD may help physicians to individualize treatment 55633 2
... National Human Genome Research Institute (NHGRI), part of the ... identified six more genetic variants involved in type 2 ... risk factors associated with increased risk of the disease. ... study had previously been suspected of playing a role ...
... ANN ARBOR, Mich.---Scientists have identified six new genes which play ... among the group is the second gene known to also ... bring the total number of genes or genomic regions implicated ... in the Department of Biostatistics. Researchers from the University of ...
... that can be applied in the study of other ... in collaboration with colleagues at the University of Washington ... have identified multiple, individually rare gene mutations in people ... illness is caused. , The team screened ...
Other Biology News:Major collaboration uncovers surprising new genetic clues to diabetes 2Major collaboration uncovers surprising new genetic clues to diabetes 3Potential association of type 2 diabetes genes with prostate cancer 2CSHL scientists part of team that discovers role of rare gene mutations in schizophrenia 2CSHL scientists part of team that discovers role of rare gene mutations in schizophrenia 3
...
SHEEP ANTI ESCHERICHIA COLI...
RayBio Human Chemokine Antibody Array 1.1 (8) with Accessory, detects 38 chemokine factors (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
... Multi-Sample Freezing-point Osmometer for 30 L samples, featuring 24-position turntable. Provides up to 30 minutes ... and software for statistical analysis and record keeping. RS-232 port. ... ... ...
Biology Products: